Aktis Oncology initiated with a Buy at TD Cowen

TD Cowen analyst Tyler Van Buren initiated coverage of Aktis Oncology (AKTS) with a Buy rating and no price target The firm says the company’s miniprotein technology has the opportunity to access radiotherapy “white space.” AKY-1189 and AKY-2519 have demonstrated durable tumor retention with minimal healthy tissue exposure, which de-risks the upcoming studies, the analyst tells investors in a research note. TD estimates over $5B in combined 2035 sales.